Epicrispr Biotechnologies
South San Francisco, California, United States · Biotechnology, Genetics, Health Care
Epicrispr Biotechnologies is a biotechnology company focused on developing curative therapies for genetic neuromuscular diseases. Their lead program, EPI-321, is a first-in-class disease-modifying therapy for facioscapulohumeral muscular dystrophy (FSHD). The company aims to advance innovative treatments that address the underlying causes of genetic disorders. With recent funding, Epicrispr is ent
Key facts
- Headquarters
- South San Francisco, California, United States
- Employees
- 38
- Industries
- Biotechnology, Genetics, Health Care
- Status
- Private
- Website
- epicrispr.com
- Company page
Recent activity at Epicrispr Biotechnologies
- : Epicrispr Biotechnologies closed a $90 million Series C financing round, led by Octagon Capital and Janus Henderson Investors, to push EPI-321 into pivotal trials.
- : Epicrispr Biotechnologies and Forge Biologics Announce Strategic Partnership for AAV Development and Manufacturing of EPI-321.
- : Epicrispr Biotechnologies Partners with Springbok Analytics to Integrate AI Muscle Analysis in First-in-Human FSHD Study
- : Epicrispr Biotechnologies has secured $68 million in Series B financing to support the clinical development of its disease-modifying therapy EPI-321. The financing was led by Ally Bridge Group with participation from SOLVE FSHD.
Epicrispr Biotechnologies funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2026 | Series C | $176.8M |
| Mar 2025 | Series B | $68.0M |
Leadership
- Alexandra, Vice President, Therapeutics
- Daniel, Head of Technology Development
- Weston Miller, Chief Medical Officer
- Amber Salzman, Chief Executive Officer
Verified email and direct lines for Epicrispr Biotechnologies’s decision-makers are on Fundz. See plans
Employee benefit plans
Epicrispr Biotechnologies files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Epicrispr Biotechnologies in the news
- Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD - Business Wire (Aug 11, 2026)
- Epicrispr bags $90M to rewrite treatment of rare muscle disease - Fierce Biotech (Aug 11, 2026)
- Epicrispr Biotechnologies and Forge Biologics Announce AAV Development and cGMP Manufacturing Partnership - Business Wire (May 05, 2026)
- Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease - BioPharma Dive (Aug 11, 2026)
- Epicrispr Biotechnologies to Begin Clinical Trials for its Lead Epigenetic Therapy for FSHD Patients - Genetic Engineering and Biotechnology News (Mar 27, 2025)
- CEO raises an Epic round of $90 million to tackle disease that hit her family - San Francisco Business Times - The Business Journals (Aug 11, 2026)
- Epicrispr Biotechnologies Secures $68 Million Series B to Initiate Clinical Trial for First-in-Class Disease-Modifying Epigenetic Neuromuscular Therapy for FSHD - BioSpace (Mar 27, 2025)
- Epicrispr Biotechnologies Presents Data on Powerful Gene Reactivation with GEMS Epigenetic Editors at ESGCT - globenewswire.com (Oct 22, 2024)
Companies similar to Epicrispr Biotechnologies
- Typewriter Therapeutics · Biotechnology, Genetics, Health Care, Therapeutics
- AAVantgarde Bio · Biotechnology, Genetics, Health Care, Therapeutics
- Applied StemCell · Biotechnology, Genetics, Health Care, Therapeutics
- Exegenesis Bio · Biotechnology, Genetics, Health Care, Therapeutics
- Franklin Biolabs · Biotechnology, Genetics, Health Care, Therapeutics
About Epicrispr Biotechnologies: questions and answers
What does Epicrispr Biotechnologies do?
Epicrispr Biotechnologies is a biotechnology company focused on developing curative therapies for genetic neuromuscular diseases. Their lead program, EPI-321, is a first-in-class disease-modifying therapy for facioscapulohumeral muscular dystrophy (FSHD). The company aims to advance innovative treatments that address the underlying causes of genetic disorders. With recent funding, Epicrispr is ent
Where is Epicrispr Biotechnologies headquartered?
Epicrispr Biotechnologies is headquartered in South San Francisco, California, United States.
How many employees does Epicrispr Biotechnologies have?
Epicrispr Biotechnologies has about 38 employees.
Has Epicrispr Biotechnologies raised funding?
Yes. Fundz has recorded 2 funding events for Epicrispr Biotechnologies. The most recent, Series C of $176.8M, was in Aug 2026.
Who leads Epicrispr Biotechnologies?
Alexandra is a Vice President, Therapeutics at Epicrispr Biotechnologies.
What is the latest news on Epicrispr Biotechnologies?
On Aug 10, 2026, Epicrispr Biotechnologies closed a $90 million Series C financing round, led by Octagon Capital and Janus Henderson Investors, to push EPI-321 into pivotal trials.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy